Skip to main content

Early safety

Very often, the development of New Chemical Entities (NCE) must be stopped following abnormal toxicity, safety margin issue, mutagenicity, cardiovascular or neurological adverse effects. To detect these deleterious events as early as possible, ERBC conducts exploratory safety programs combining in vitro and in vivo toxicity assays (in rodent and non-rodent species) and predictive biomarkers. 

To optimize the costs and timing, the administrative work is minimized as much as possible, the experimental procedures are described in standard study plans, and all details specific to each study will be described in an information study sheet.

Low costs are also achieved through reduction of animal number while sensitivity is maintained by using low variability model, appropriate statistical designs (2 biostatisticians in the team) and application of very powerful approach such as the probabilistic method. In the same way, a summary report including the results of each test in each model, the interpretation of results and a description of the experimental methods are issued just after the end of the ultimate experimental phase (less than 2 weeks after the last experimentation).

GLP certified
our expertise by

Therapeutic areas

Cardiology

Neurology

Pneumology

Oncology

Immuno-oncology

Allergy

Dermatology

Gastro-enterology

Analgesia/inflammation

Endocrinology

Haematology

Nephrology

A comprehensive range of preclinical models for short and long-term toxicology studies

Our animal models

John joe

Mouse

John joe

Rat

John joe

Dog

John joe

Rabbit

John joe

Marmoset

John joe

Ferret

John joe

Cynomolgus Monkeys

John joe

Guinea Pig

John joe

Cat

John joe

Hamster

John joe

MiniPig

A wide range of services that span the entire drug discovery and development continuum and can be tailored to specific research conditions

Our Services

NEED TO CREATE YOUR

UNIQUE PROJECT

Each project is managed by a study director, relying on a multi-disciplinary team of experts.